$GERN

Geron (GERN) anticipates RYTELO revenue near the high end of 2026 guidance, with over one-third of patients now in earlier treatment lines. The company plans to update its European strategy by year-end, considering partnerships or targeted commercial activities. Geron has $320M in cash and is evaluating business development opportunities. RYTELO is approved for certain myelodysplastic syndromes.

Geron Corp. (GERN) reported Q4 2025 revenue of $48M, missing estimates, with an EPS loss of $0.05. RYTELO sales grew 9% QoQ to $48M. The stock fell 10% premarket. Operating costs were $254.7M, with restructuring charges of $17M. Geron projects 2026 RYTELO revenue of $220M-$240M.

Geron Corp (GERN) shares rose 14.7% after the company issued its first full-year 2026 RYTELO revenue guidance of $220 million to $240 million. Geron reported Q2 revenue of $57.48 million and a net loss of $16.68 million. For the first half, revenue was $109.32 million with a $20.32 million net loss, alongside discussion of analyst price targets.

Simply Wall St reports Geron (GERN) issued 2026 earnings guidance tied to RYTELO net product revenue and released Q2 and half-year 2026 results on Aug 5. The article cites a $1.48 share price, guidance and updated revenue and net loss figures, and a “fair value” estimate of $3.40 versus $1.48, with a consensus price target of $3.625.

Geron (NASDAQ:GERN) said about 8,000 U.S. patients may be eligible for RYTELO in second-line, lower-risk MDS. The company guided 2026 RYTELO net product revenue to the mid-to-high end of $220 million to $240 million and expects operating expenses of $230 million to $240 million. Q2 gross-to-net deductions rose to 20.7%.

GERON CORP (GERN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 5, 2026 Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product rev

Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.

Geron Corporation reported Q2 2026 results on its RYTELO business, citing 17% year-over-year net revenue growth and 24% net revenue growth in the first half of 2026 with total operating expenses down 4%. Full-year 2026 RYTELO net revenue guidance is $220M to $240M. Cash was $327M. Operating expenses guidance is $230M to $240M.

The article lists 10 “fastest growing” tech penny stocks under $5, using a Finviz screen for over 50% compounded annual revenue growth in 3 years and recent catalysts. It highlights PowerFleet (NASDAQ:AIOT) launching SafeGuard, reporting up to 83% on-road risk reduction, and approving a $30M repurchase. It also covers Geron (NASDAQ:GERN) granting 690,000 options at $1.23.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron ( GERN ) To Contact Him Directly To Discuss Their Options